Asian Pacific Journal of Cancer Prevention

  • 제13권8호
  • /
  • Pages.3555-3560
  • /
  • 2012
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Tumour Lysis Syndrome: Implications for Cancer Therapy

  • Mika, Denish (Department of Biotechnology, Karunya University) ;
  • Ahmad, Sabrina (Department of Biotechnology, Karunya University) ;
  • Guruvayoorappan, C. (Department of Biotechnology, Karunya University)
  • 발행 : 2012.08.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

The tumour lysis syndrome (TLS) is a group of metabolic abnormalities caused by rapid and unexpected release of cellular components into the circulation as a result of massive destruction of rapidly proliferating malignant cells. It usually develops in patients with hematologic malignancies like acute lymphoid leukemia, non-Hodgkin and Burkitt's lymphoma after initiation of chemotherapy or may, rarely, occur spontaneously. Though TLS is seldom observed in relation to solid tumours, there have been reports of connections with examples such as lung, liver, breast, gastric carcinomas. The clinical manifestations of TLS include hyperuricemia, hyperkalemia, hyperphosphatemia and hypocalcemia. These indications if untreated lead to life-threatening complications such as acute renal failure, cardiac arrhythmias, seizures, and eventually death due to multiorgan failure. Therefore early detection of TLS is of vital importance. This can be accomplished by identification of high risk patients, implementation of suitable prophylactic measures andmonitoring of the electrolyte levels in patients undergoing chemotherapy.

키워드

참고문헌

  1. Annemans L, Moeremans K, Lamotte M, et al (2003). Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin's lymphoma in four European countries. Leuk Lymphoma, 44, 77-83. https://doi.org/10.1080/1042819021000054661
  2. Arrambide K, Toto RD (1993). Tumor lysis syndrome. Semin Nephrol, 13, 273-80.
  3. Band PR, Silverberg DS, Henderson JF, et al (1970). Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol. N Engl J Med, 283, 354-7. https://doi.org/10.1056/NEJM197008132830708
  4. Bosly A, Sonet A, Pinkerton CR, et al (2003). Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer, 98, 1048-54. https://doi.org/10.1002/cncr.11612
  5. Cairo MS, Bishop M (2004). Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol, 127, 3-11. https://doi.org/10.1111/j.1365-2141.2004.05094.x
  6. Cairo M S, Coenelis M, Baruchel A, et al (2007). Risk assessment and medical decision model for prophylaxis and treatment of hyperuricemia and tumor lysis syndrome (TLS): international expert panel analysis. J Clin Oncol, 25, 17006.
  7. Cammalleri L, Malaguarnera M (2007). Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout. Int J Med Sci, 4, 83-93.
  8. Cheson B D, Dutcher B S (2005). Managing malignancyassociated hyperuricemia with rasburicase. J Support Oncol, 3, 117-24.
  9. Conger J D, Falk S A, Guggenheim S J, Burke T J (1976). A micropuncture study of the early phase of acute urate nephropathy. J Clin Invest, 58, 681-9. https://doi.org/10.1172/JCI108514
  10. Coiffier B, Mounier N, Bologna S, et al (2003). Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol, 21, 4402-6. https://doi.org/10.1200/JCO.2003.04.115
  11. Davidson M B, Thakkar S, Hix J K, et al (2004). Pathophysiology, clinical consequences and treatment of tumour lysis syndrome. Am J Med, 116, 546-4. https://doi.org/10.1016/j.amjmed.2003.09.045
  12. DeConti R C, Calabresi P (1966). Use of allopurinol for prevention and control of hyperuricemia in patients with neoplastic disease. N Engl J Med, 274, 481-6. https://doi.org/10.1056/NEJM196603032740902
  13. Del Toro G, Morris E, Cairo M S (2005). Tumor lysis syndrome: pathophysiology, definition, and alternative treatment approaches. Clin Adv Hematol Oncol, 3, 54-61.
  14. Drakos P, Bar-Ziv J, Catane R (1994). Tumor lysis syndrome in nonhematologic malignancies. Report of a case and review of the literature. Am J Clin Oncol, 17, 502-5. https://doi.org/10.1097/00000421-199412000-00010
  15. Fleming D R, Doukas M A (1992). Acute tumor lysis syndrome in hematologic malignancies. Leuk Lymphoma, 8, 315-8. https://doi.org/10.3109/10428199209051009
  16. Goldman S C, Holcenberg J S, Finklestein J Z, et al (2001). A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood, 97, 2998-3003. https://doi.org/10.1182/blood.V97.10.2998
  17. Hande K R, Garrow G C (1993). Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med, 94, 133-9. https://doi.org/10.1016/0002-9343(93)90174-N
  18. Hecht J L, Aster J C (2000). Molecular biology of Burkitt's lymphoma. J Clin Oncol, 18, 3707-21. https://doi.org/10.1200/JCO.2000.18.21.3707
  19. Hijiya N, Metzger M L, Pounds S, et al (2005). Severe cardiopulmonary complications consistent with systemic inflammatory response syndrome caused by leukemia cell lysis in childhood acute myelomonocytic or monocytic leukemia. Pediatr Blood Cancer, 44, 63-9. https://doi.org/10.1002/pbc.20192
  20. Hochberg J, Cairo M S (2008). Tumor lysis syndrome: current perspective. Haematologica, 93, 67-74. https://doi.org/10.3324/haematol.11575
  21. Hogan D K, Rosenthal L D (1998). Oncologic emergencies in the patient with lymphoma. Semin Oncol Nurs, 14, 312-20. https://doi.org/10.1016/S0749-2081(98)80009-0
  22. Jeha S (2001). Tumor lysis syndrome. Semin Hematol, 38, 4-8. https://doi.org/10.1053/shem.2001.25183
  23. Kadar N, Krumerman M (1995). Possible metaplastic origin of lymph node "metastases" in serous ovarian tumor of low malignant potential (borderline serous tumor). Gynecol Oncol, 59, 394-7. https://doi.org/10.1006/gyno.1995.9955
  24. Klinenberg J R, Goldfinger S, Seegmiller J E (1965). The effectiveness of the xanthine oxidase inhibitor allopurinol in the treatment of gout. Ann Intern Med, 62, 639-47. https://doi.org/10.7326/0003-4819-62-4-639
  25. Klinenberg J R, Kippen I, Bluestone R (1975). Hyperuricemic nephropathy: pathologic features and factors influencing urate deposition. Nephron, 14, 88-98. https://doi.org/10.1159/000180438
  26. Krakoff I H, Meyer R L (1965). Prevention of hyperuricemia in leukemia and lymphoma: use of allopurinol, a xanthine oxidase inhibitor. JAMA, 193, 1-6. https://doi.org/10.1001/jama.1965.03090010007001
  27. Lawrence J (1994). Critical care issues in the patient with hematologic malignancy. Semin Oncol Nurs, 10, 198-207. https://doi.org/10.1016/S0749-2081(05)80086-5
  28. Landgrebe A R, Nyhan W L, Coleman M (1975). Urinary-tract stones resulting from the excretion of oxypurinol. N Engl J Med, 292, 626-7. https://doi.org/10.1056/NEJM197503202921208
  29. Levine A M (2002). Challenges in the management of Burkitt's lymphoma. Clin Lymphoma, 3, 19-25. https://doi.org/10.3816/CLM.2002.s.011
  30. Lorigan P C, Woodings P L, Morgenstern G R, Scarffe J H (1996). Tumour lysis syndrome, case report and review of the literature. Ann Oncol, 7, 631-6. https://doi.org/10.1093/oxfordjournals.annonc.a010682
  31. Mahmoud H H, Leverger G, Patte C, Harvey E, Lascombes F (1998). Advances in the management of malignancyassociated hyperuricaemia. Br J Cancer, 77, 18-20.
  32. Mandal A K (1997). Hypokalemia and hyperkalemia. Med Clin North Am, 81, 611-39. https://doi.org/10.1016/S0025-7125(05)70536-8
  33. Mayne N, Keady S, Thacker M (2008). Rasburicase in the prevention and treatment of tumour lysis syndrome. Intensive Crit Care Nurs, 24, 59-62. https://doi.org/10.1016/j.iccn.2007.06.002
  34. Monbalyu J, Zachee P, Verberckmoes R, Boogaerts MA (1984). Transient acute renal failure due to tumor-lysis-induced severe phosphate load in a patient with Burkitt's lymphoma. Clin, Nephrol, 22, 47-50.
  35. Montesinos P, Lorenzo I, Martín G, et al (2008). Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica, 93, 67-74. https://doi.org/10.3324/haematol.11575
  36. Nakamura M, Oda S, Sadahiro T, et al (2009). The role of hypercytokinemia in the pathophysiology of tumor lysis syndrome (TLS) and the treatment with continuous hemodiafiltration using a polymethylmethacrylate membrane hemofilter (PMMA-CHDF). Transfus Apher Sci, 40, 41-7. https://doi.org/10.1016/j.transci.2008.11.004
  37. Navolanic P M, Pui C H, Larson R A, et al (2003). Elitekrasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002. Leukemia, 17, 499-514. https://doi.org/10.1038/sj.leu.2402847
  38. Oda M, Satta Y, Takenaka O, Takahata N (2002). Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol Biol Evol, 19, 640-53. https://doi.org/10.1093/oxfordjournals.molbev.a004123
  39. Overgaard K, Nielsen O B, Clausen T (1997). Effects of reduced electrochemical Na+ gradient on contractility in skeletal muscle: role of the $Na^{+}-K^{+}$ pump. Pflugers Arch, 434, 457-65. https://doi.org/10.1007/s004240050421
  40. Pak C Y (1969). Physicochemical basis for formation of renal stones of calcium phosphate origin: calculation of the degree of saturation of urine with respect to brushite. J Clin Invest, 48, 1914-22. https://doi.org/10.1172/JCI106158
  41. Patte C, Sakiroglu C, Ansoborlo S, et al (2002). Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Société Française d'Oncologie Pédiatrique LMB89 protocol. Ann Oncol, 13, 789-95. https://doi.org/10.1093/annonc/mdf134
  42. Razis E, Arlin Z, Ahmed T (1994). Incidence and treatment of tumour lysis syndrome in patients with acute leukaemia. Acta Haematol, 91, 171-4. https://doi.org/10.1159/000204328
  43. Ribeiro R C, Pui C H (2002). Hyperuricemia in patients with cancer. Am J Cancer, 1, 409-22. https://doi.org/10.2165/00024669-200201060-00004
  44. Rieselbach R E, Bentzel C J, Cotlove E, et al (1964). Uric acid excretion and renal function in the acute hyperuricemia of leukemia: pathogenesis and therapy of uric acid nephropathy. Am J Med, 37, 872-83. https://doi.org/10.1016/0002-9343(64)90130-5
  45. Spector T (1977). Inhibition of urate production by allopurinol. Biochem. Pharmacol, 26, 355-8. https://doi.org/10.1016/0006-2952(77)90191-5
  46. Soares M, Feres G A, Salluh J I (2009). Systemic inflammatory response syndrome and multiple organ dysfunction in patients with acute tumor lysis syndrome. Clinics (Sao Paulo), 64, 479-81. https://doi.org/10.1590/S1807-59322009000500016
  47. Stapleton F B, Strother D R, Roy S, et al (1988). Acute renal failure at onset of therapy for advanced stage Burkitt lymphoma and B cell acute lymphoblastic lymphoma. Pediatrics, 82, 863-9.
  48. Tannock I (1978). Cell kinetics and chemotherapy: a critical review. Cancer Treat Rep, 62, 1117-33.
  49. Tsokos G C, Balow J E, Spiegel R J, Magrath I T (1981). Renal and metabolic complications of undifferentiated and lymphoblastic lymphomas. Medicine (Baltimore), 60, 218-29. https://doi.org/10.1097/00005792-198105000-00005
  50. Veenstra J, Krediet R T, Somers R, Arisz L (1994). Tumour lysis syndrome and acute renal failure in Burkitt's lymphoma. Description of 2 cases and a review of the literature on prevention and management. Neth J Med, 45, 211-6.
  51. Wossmann W, Schrappe M, Meyer U, Zimmermann M, Reiter A (2003). Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urateoxidase. Ann Hematol, 82, 160-5.
  52. Wilcox W R, Khalaf A, Weinberger A, Kippen I, Klinenberg J R (1972). Solubility of uric acid and monosodium urate. Med Biol Eng, 10, 522-31. https://doi.org/10.1007/BF02474201
  53. Yarpuzlu A A (2003). A review of clinical and laboratory findings and treatment of tumor lysis syndrome. Clin Chim Acta, 333, 13-8. https://doi.org/10.1016/S0009-8981(03)00166-9
  54. Zojer N, Ludwig H (2007). Hematological emergencies. Ann Oncol, 18, 45-8. https://doi.org/10.1093/annonc/mdl450

피인용 문헌

  1. Serum uric acid levels and cancer mortality risk among males in a large general population-based cohort study vol.25, pp.8, 2014, https://doi.org/10.1007/s10552-014-0408-0
  2. Concurrent acute spontaneous tumor lysis syndrome complicated with multiple organ failure in a patient with pre-existing undiagnosed lung cancer vol.4, pp.2, 2015, https://doi.org/10.1007/s13730-015-0175-0
  3. A review in the treatment of oncologic emergencies vol.22, pp.4, 2016, https://doi.org/10.1177/1078155215605661